In summary, HSPA7 facilitated tumor promoting macrophage migration into the GBM TME by activating the YAP1–LOX axis, and our results indicated that HSPA7 might be a potential immunotherapy target for GBM patients. This evidence concerns the gene YAP1 and glioblastoma.